Thermo Fisher Scientific Launches Groundbreaking Obesity Registry

Obesity is not merely a cosmetic issue; it is a chronic disease that presents numerous health challenges. The condition is multifactorial, influenced by genetic, environmental, and psychosocial factors, and is linked to severe comorbidities such as type 2 diabetes, heart disease, and various cancers. In the U.S. alone, over 100 million adults are affected by obesity, with more than 22 million experiencing severe forms of the disease. The economic implications are staggering, with the World Health Organization projecting costs associated with overweight and obesity to soar to $3 trillion annually by 2030, and potentially surpassing $18 trillion by 2060.

The CorEvitas Obesity Registry is designed to gather comprehensive data from both clinicians and patients. By focusing on treatment patterns, adherence, satisfaction, and clinical outcomes—including critical anthropometric measures—the registry aims to create a robust evidence base that reflects the complexities of obesity management in real-world settings.

Leslie Harrold, M.D., Vice President and Global Head of Real-World Science and Strategy for PPD CorEvitas Clinical Registries at Thermo Fisher, emphasized the significance of this initiative: “The CorEvitas Obesity Registry represents a major step forward in understanding the use and outcomes associated with obesity treatments in everyday clinical practice. Insights generated from this robust, real-world evidence base will inform the healthcare community on treatment effectiveness, safety, and the patient experience associated with obesity care, which will advance care for millions living with the condition.”

The registry is expected to provide valuable insights into disease progression, treatment response, and the challenges faced by patients throughout their care journey. The findings will not only inform clinical practice but also guide future research and support the development of evidence-based strategies for managing obesity.

This initiative marks the 15th independent registry established under the PPD™ CorEvitas™ Clinical Registries, which is part of the PPD clinical research business of Thermo Fisher Scientific. The CorEvitas Clinical Registries are recognized for their proprietary disease registries that encompass structured, regulatory-grade patient clinical data across more than 500 investigator sites. The extensive longitudinal data collected from over 100,000 patients will enhance the reliability and validity of the findings.

The independent registry model employed by CorEvitas has been accepted by regulators for long-term post-authorization safety studies across various disease indications. This acceptance underscores the credibility and importance of the data being collected, paving the way for improved clinical decision-making and patient care.

Thermo Fisher Scientific's launch of the CorEvitas Obesity Registry signifies a pivotal moment in the fight against obesity. By harnessing real-world evidence, the registry aims to transform how obesity is treated and understood, ultimately improving outcomes for millions of individuals worldwide. As the healthcare community continues to grapple with the complexities of this chronic disease, initiatives like this one will be crucial in advancing care and fostering better health outcomes.

For more information about the CorEvitas Clinical Registries and the newly launched obesity registry, interested parties can reach out directly to Thermo Fisher.